Message from the Director of the Department
We provide comprehensive medical services and care for various hematopoietic disorders. Furthermore, more than 50 hematopoietic stem cell transplantations are performed each year for the treatment of lymphoma, leukemia, and myelodysplastic and myeloproliferative syndromes. As a core hospital for promotion of hematopoietic stem cell transplantation, we are promoting assistance to the development of transplantation in the westernmost region of Honshu, the largest island of Japan.
Director,
Department of Hematology and
OncologyYoshinobu Maeda
Scope of Target Diseases
We provide care for various hematopoietic disorders, from hematological malignancies such as leukemia, myelodysplastic syndromes, malignant lymphoma, and multiple myeloma, to non-malignant diseases, such as aplastic anemia, hemolytic anemia, polycythemia, thrombocytopenic purpura, and coagulation disorder.
Features and Description of Medical Care
For malignant hematopoietic disease, state-of-the-art treatment is performed particularly, such as the clinical trials of new drugs, new clinical studies, and hematopoietic stem cell transplantation(HSCT). We perform HSCT in one of the largest number of cases among national and public university hospitals in Japan. We have 14 beds to perform HSCT in the Biological Clean Room (BCR). We perform around 50 cases of allogeneic HSCT actively as the central institution for HSCT in the Chugoku and Shikoku regions.
Moreover, we have been performing CAR-T cell therapy for refractory/relapsed acute lymphoblastic leukemia, diffuse large B cell lymphoma and multiple myeloma since the end of 2019.
The outpatient clinic run by specialists is available daily. For hospital treatment, the treatment policy and observations of each patient are discussed every week. For hematopoietic cell transplantation, a joint conference by doctors, pharmacists, dentists, nurses, psychiatrists and rehabilitation doctors, etc. is held every week to address the multifaceted problems related to disease. Furthermore, allogeneic transplant patients will be seen regularly by our multidisciplinary team in the hematopoietic stem cell transplantation long-term follow-up program.
